1. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Issue 7 (July 2020) Authors: Volc, Dieter; Poewe, Werner; Kutzelnigg, Alexandra; Lührs, Petra; Thun-Hohenstein, Caroline; Schneeberger, Achim; Galabova, Gergana; Majbour, Nour; Vaikath, Nishant; El-Agnaf, Omar; Winter, Dorian; Mihailovska, Eva; Mairhofer, Andreas; Schwenke, Carsten; Staffler, Günther; Medori, Rossella Journal: Lancet neurology Issue: Volume 19:Issue 7(2020) Page Start: 591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗